Table 2.
Expression of costimulatory molecules (CD40L and ICOS) in PHA+IL-2 stimulated PBMC from CVID patients and N.
| Costimulatory molecules expression in CD4+ lymphocytes (%, mean ± SE) | ||||
|---|---|---|---|---|
| CD40L+ | CXCR5+CD40L+ | ICOS | CXCR5+ICOS+ | |
| Group I (n = 4) | ||||
| Medium | 1.8 ± 2 | 1.7 ± 1.2 | 3.0 ± 0.2 | 2.2 ± 1.7 |
| PHA+IL-2 | 11.0 ± 3.7 | 9.4 ± 3.5 | 24.4 ± 8.2 | 17.0 ± 5.3 |
| Group II (n = 4) | ||||
| Medium | 2.4 ± 2 | 1.9 ± 1.1 | 4.3 ± 1.8 | 3.0 ± 1.7 |
| PHA+IL-2 | 11.5 ± 4.1 | 10.3 ± 4.2 | 22.8 ± 9.0 | 15.6 ± 6.5 |
| Normals (n = 7) | ||||
| Medium | 2.3 ± 1.5 | 2.0 ± 1.3 | 2.8 ± 3.2 | 1.8 ± 0.9 |
| PHA+IL-2 | 7.3 ± 1.5 | 6.4 ± 1.5 | 16.3 ± 1.8 | 7.2 ± 1.1 |
PBMC were stimulated with 2.5 μg/mL phytohemmagglutinin and 5 UI/mL interleukin-2 for 2 days and then were stained with anti-CD4, anti-CXCR5 and either anti-CD40L or anti-ICOS. The percentage of CD4+ cells that express CD40L, CXCR5 plus CD40L, ICOS and CXCR5 plus ICOS is consigned. No significant differences were observed between both CVID groups and Normals.